Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 20, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 22, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-019273
Filed / recorded
Jan 22, 2026, 7:11 PM UTC
Added to OQRO
Oct 8, 2026, 2:22 AM UTC
Parser
form4-xml-v2
Data quality
Needs review
Issuer
ATOSSA THERAPEUTICS, INC.
Issuer CIK
1488039
Ticker
ATOS
Reporting person
Steven C Quay
Relationship
Director, Officer
Officer title
President & CEO
Security
Stock Options (right to buy)
Table
Derivative (Table II)
Transaction date
Jan 20, 2026
Transaction code
A
Shares / units
950,000
Price per share
$0.603
Acquired / disposed
Acquired (A)
Shares owned after
950,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.